Rigel Pharmaceuticals, Inc. (RIGL) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $50.97 (-0.93%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jun 8, 2022 | Eun Yang | Jefferies | $1.00 | -98.0% |
Top Analysts Covering RIGL
RIGL vs Sector & Market
| Metric | RIGL | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.12 | 2.25 | 2.41 |
| Analyst Count | 8 | 8 | 19 |
| Target Upside | +31.4% | +153002.0% | +21.5% |
| P/E Ratio | 2.72 | 3.47 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $76M | $78M | $79M | 2 |
| 2027-03-31 | $67M | $69M | $70M | 1 |
| 2027-06-30 | $73M | $75M | $77M | 2 |
| 2027-09-30 | $79M | $81M | $83M | 2 |
| 2027-12-31 | $84M | $86M | $88M | 1 |
| 2028-12-31 | $356M | $356M | $356M | 5 |
| 2029-12-31 | $347M | $359M | $377M | 2 |
| 2030-12-31 | $375M | $388M | $407M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.09 | $1.12 | $1.15 | 1 |
| 2027-03-31 | $0.60 | $0.62 | $0.64 | 1 |
| 2027-06-30 | $0.84 | $0.87 | $0.90 | 1 |
| 2027-09-30 | $0.92 | $0.94 | $0.97 | 1 |
| 2027-12-31 | $1.09 | $1.12 | $1.15 | 1 |
| 2028-12-31 | $3.22 | $4.44 | $5.84 | 4 |
| 2029-12-31 | $3.08 | $3.22 | $3.44 | 2 |
| 2030-12-31 | $3.62 | $3.79 | $4.04 | 2 |
Frequently Asked Questions
What is the analyst consensus for RIGL?
The consensus among 8 analysts covering Rigel Pharmaceuticals, Inc. (RIGL) is Buy with an average price target of $67.00.
What is the highest price target for RIGL?
The highest price target for RIGL is $1.00, set by Eun Yang at Jefferies on 2022-06-08.
What is the lowest price target for RIGL?
The lowest price target for RIGL is $1.00, set by Eun Yang at Jefferies on 2022-06-08.
How many analysts cover RIGL?
8 analysts have issued ratings for Rigel Pharmaceuticals, Inc. in the past 12 months.
Is RIGL a buy or sell right now?
Based on 8 analyst ratings, RIGL has a consensus rating of Buy (2.12/5) with a +31.4% upside to the consensus target of $67.00.
What are the earnings estimates for RIGL?
Analysts estimate RIGL will report EPS of $1.12 for the period ending 2026-12-31, with revenue estimated at $78M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.